Bank of Montreal
XENE icon

Bank of Montreal’s Xenon Pharmaceuticals XENE Stock Holding History

Bank of Montreal’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-39,500
Closed -$1.71M – 4289
2024
Q1 		$1.71M Buy
+39,500
New +$1.82M ﹤0.01% 1718

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of Montreal's XENE Position: Q2 2024 in Review

Bank of Montreal sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 909 shares — an estimated $39.3K sold.

Bank of Montreal first reported a position in XENE in Q2 2015 and held it in 27 quarters. The position peaked at $7.83M in Q2 2023. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • Bank of Montreal reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bank of Montreal sold 909 Xenon Pharmaceuticals shares in Q2 2024, an estimated $39.3K.
  • Bank of Montreal first reported a position in Xenon Pharmaceuticals in Q2 2015 and held it in 27 quarters.
  • Bank of Montreal's Xenon Pharmaceuticals position peaked at $7.83M in Q2 2023.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on Bank of Montreal's 13F filing for Q2 2024, filed 14 Aug 2024.